A phase II trial of CI-921 in advanced malignancies
Autor: | J. Leiby, A. Mittelman, Pj. Rosen, Francois Robert, Jacques Longueville, Lc. Panasci, Jacques Jolivet, Ja. Stewart, Am. Vandermerwe, Jc. Ruckdeschel, De. Bergsagel, Laura Benson, Nt. Sklarin, Ph. Wiernik, Wr. Grove, Jh. Doroshow, Nj. Robert, Cd. Kowal, Enrique Velez-Garcia, Ja. Maroun |
---|---|
Rok vydání: | 1992 |
Předmět: |
Adult
Amsacrine Male medicine.medical_specialty Nausea medicine.medical_treatment Antineoplastic Agents Gastroenterology Drug Administration Schedule Breast cancer Internal medicine Neoplasms medicine Humans Pharmacology (medical) Aged Pharmacology Chemotherapy Leukopenia Lung business.industry Melanoma Stomach Middle Aged medicine.disease Surgery medicine.anatomical_structure Treatment Outcome Oncology Vomiting Female medicine.symptom business |
Zdroj: | Investigational new drugs. 10(4) |
ISSN: | 0167-6997 |
Popis: | CI-921, (9-[[2-methoxy-4-[(methylsulfonyl)amino]phenyl]amino]- N,5-dimethyl-4-acridinecarboxamide 2-hydroxyethanesulfonate (1:1)), an anilinoacridine derivative with activity in experimental solid tumors was studied in a multicenter phase II trial in patients with solid tumors. Eligible tumor types included cancers of the breast, stomach, pancreas, nonsmall cell lung, small cell lung, colon, head and neck area, and melanoma. Prestudy requirements included an ECOG performance status ofor = 2, no CNS metastases, and measurable disease. CI-921 was administered intravenously over 1-2 hours on days 1, 8, and 15 of a 35-day course at an initial dose of 270 mg/M2, with modification in subsequent courses based upon tolerance. Principal toxicities included leukopenia, marked phlebitis, and mild nausea and vomiting. One hundred fifty patients were entered of whom 132 were evaluable for response. There was one complete and one partial response among 19 patients with breast cancer, and two partial responses, one each among 14 head and neck and 36 nonsmall cell lung cancer patients. |
Databáze: | OpenAIRE |
Externí odkaz: |